What happened
JW Pharmaceutical filed provisional (unaudited) separate results for Q2 2026: revenue of US$156M (+16.1% year on year), operating profit of US$23.9M (+32.7% year on year) and net income of US$19.2M (from a loss a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$156M |
|---|---|
| Revenue vs a year earlier | +16.1% |
| Operating profit | US$23.9M |
| Net income | US$19.2M |
| Period | Q2 2026 (separate) |
| Filed | 2026-08-11, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260811800829 → open original filing |
Source: DART. Information only, not investment advice.